EPO的市场

中外制药公司1月21日开始在南朝鲜销售重组促红细胞生成素(EPO).同日由台湾批准在台湾销售.打算年内也在新加坡、香港等地销售,然后扩大到菲律宾、澳大利亚和新西兰.在美国与美国Upjhon公司联合设立的Chugai Upjhon公司正在申请生产此药.该公司比美国先行一步,在亚洲扩大了实用化.EPO已成为中外制药在世界战略的尖兵. 在南朝鲜销售重组EPO的是南朝鲜中外公司.该公司在战前就与中外制药有关系,但是现在没有资本关系.另外,在台湾,是由中外制药的销售事务所直接销售.EPO都是在日本     

EPO法律纠纷仍未结案

在有关红血细胞生长因子红细胞蛋白(EPO)的法律纠纷中,Amgen Inc.对Genetics Institute Inc.(GI)给予防御性还击。Amgen公司对美国地方法庭的裁决表示不满,认为GI近期中请的EPO专利无效且不能执行,因此GI无权向Amgen要求任何专利权。 在本年六月,GI对Amgen许可证持有机构Ortho Pharmaceuticals Crop提出诉讼,宣称Ortho违     

Relaxation Kinetic Study of Eudragit? NM30D Film Based on Complex Modulus Formalism

This study is aimed at resolving and characterizing the primary (α) and secondary relaxations (β) in Eudragit® NM30D film based on apparent activation energies derived from complex modulus formalism using dielectric analysis (DEA). The glass transition (T_g) of the film was determined using differential scanning calorimetry (DSC). The α relaxation corresponding to T_g and the β relaxations occurring below T_g were probed using DEA. The occurrence of α and β relaxations in Eudragit® NM30D film was elucidated using the complex modulus of the dielectric response employing loss modulus and permittivity data. Activation energies of these relaxations and the fundamental frequency so determined support the assignment of the relaxation pattern in the Eudragit® NM30D film. DEA methodology of the complex modulus formalism is a useful tool for differentiating the α and β relaxation kinetics in Eudragits® not easily studied using traditional thermal methods such as DSC. The kinetics associated with α and β relaxations so determined will provide formulation design support for solid orals that incorporate Eudragit® polymers. As mobility changes can affect stability and diffusion, the dipolar α and β relaxations revealed through DEA analysis may enable a better correlation to functionality of Eudragit® based pharmaceutical dosage forms.KEY WORDS: activation energy, loss modulus, permittivity, primary relaxation, secondary relaxation     

A New Extrudable Form of Hypromellose: AFFINISOL™ HPMC HME

Hypromellose is a hydrophilic polymer widely used in immediate- and modified-release oral pharmaceutical dosage forms. However, currently available grades of hypromellose are difficult, if not impossible, to process by hot melt extrusion (HME) because of their high glass transition temperature, high melt viscosity, and low degradation temperature. To overcome these challenges, a modified grade of hypromellose, AFFINISOL? HPMC HME, was recently introduced. It has a significantly lower glass transition temperature and melt viscosity as compared to other available grades of hypromellose. The objective of this paper is to assess the extrudability and performance of AFFINISOL? HPMC HME (100LV and 4M) as compared to other widely used polymers in HME, including HPMC 2910 100cP (the currently available hypromellose), Soluplus®, Kollidon® VA 64, and EUDRAGIT® E PO. Formulations containing polymer and carbamazepine (CBZ) were extruded on a co-rotating 16-mm twin-screw extruder, and the effect of temperature, screw speed, and feed rate was investigated. The performance of the solid dispersions was evaluated based on Flory–Huggins modeling and characterized by differential scanning calorimetry (DSC), X-ray powder diffraction (XRD), Raman spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and dissolution. All formulations extruded well except for HPMC 2910 100cP, which resulted in over-torqueing the extruder (machine overloading because the motor cannot provide efficient energy to rotate the shaft). Among the HME extrudates, only the EUDRAGIT® E PO formulation was crystalline as confirmed by DSC, XRD, and Raman, which agreed with predictions from Flory–Huggins modeling. Dissolution testing was conducted under both sink and non-sink conditions. Sink dissolution testing in neutral media revealed that amorphous CBZ in the HME extrudates completely dissolved within 15 min, which was much more rapid than the time for complete dissolution of bulk CBZ (60 min) and EUDRAGIT® E PO solid dispersion (more than 6 h). Non-sink dissolution in acidic media testing revealed that only CBZ contained in the AFFINISOL? HPMC HME, and EUDRAGIT® E PO solid dispersions rapidly supersaturated after 15 min, reaching a twofold drug concentration compared to the CBZ equilibrium solubility. In summary, AFFINISOL? HPMC HME 100LV and AFFINISOL? HPMC HME 4M are useful in the pharmaceutical HME process to increase wetting and dissolution properties of poorly water-soluble drugs like CBZ.     

EPO工程细胞株支原体检测

支原体污染是细胞培养过程中最常见的问题之一,对细胞支原体的检测是细胞特性鉴定的重要方面。我们采用抗支原体单抗免疫荧光法和培养法(包括液体培养法和固体培养法)检测工程细胞支原体。单抗免疫荧光法检测结果表明:支原体阳性的细胞膜表面有明亮荧光,工程细胞EPO C_2细胞膜表面无荧光。支原体液体培养法结果显示:作为阳性对照的支原体由于在生长过程中产酸使培养液变黄,而加入EPOC_2株细胞悬液的样品管与阴性对照管相同,无颜色变化。固体培养法结果显示:在显微镜下观察,支原体阳性对照在固体培养基上呈荷包蛋样集落,而阴性对照及EPO C_2株细胞样品均无菌落生长。以上结果表明:受检的EPO C_2株细胞未被支原体污染。     

A simple method of chymotrypsin concentration and purification from pancreas homogenate using Eudragit® L100 and Eudragit® S100

The condition of chymotrypsin (ChTRP)–Eudragit^® (Eu) insoluble complex formation was studied with the aim of applying this information to the separation of chymotrypsin from a crude filtrate of bovine pancreas homogenate. The optimal pH of the complex precipitation was 4.60 for ChTRP–Eudragit^® L100 and 5.40 for ChTRP–Eudragit^® S100. The polyelectrolyte concentration necessary for the commercial enzyme precipitation was lower than 0.1% (w/v). The complex formation was inhibited by NaCl for both polyelectrolytes. The method was applied to recover the enzyme from bovine homogenate; ChTRP was precipitated by Eudragit^® addition. The non-soluble complexes were separated by simple centrifugation and re-dissolved by a pH change to 8.20. The best conditions to recover ChTRP brought about a purification factor of around 4 and 90% yield.     

Melt-Extruded Eudragit® FS-Based Granules for Colonic Drug Delivery

The purpose of this study is to characterize the properties of Eudragit® FS-based granules prepared using melt extrusion process for colonic drug delivery. 5-Aminosalicylic acid (5-ASA), theophylline, and diclofenac sodium were used as the model compounds. Drug and polymer blends were melt-extruded into thin rods using a single screw extruder. Drugs were found to be dispersed as crystalline particles in the granules. A hammer mill was used to reduce the extrudate into 16–40 mesh granules, which were mixed with lactose and filled into hard gelatin capsules. Three-stage dissolution testing performed using USP paddle method was used to simulate drug release in gastrointestinal tract. In this study, melt extrusion has been demonstrated to be a suitable process to prepare granules for colonic delivery of 5-amino salicylic acid. At 30% drug loading, less than 25% 5-ASA was released from melt-extruded granules of 20–30 mesh in the first two stages (0.1 N hydrochloric acid solution and phosphate buffer pH 6.8) of the dissolution testing. All 5-ASA was released within 4 h when dissolution medium was switched to phosphate buffer pH 7.4. Drug loading, granule size, and microenvironment pH induced by the solubilized drug were identified as the key factors controlling drug release. Granules prepared with melt extrusion demonstrated lower porosity, smaller pore size, and higher physical strength than those prepared with conventional compression process. Eudragit® FS was found to be stable even when processed at 200°C.     

激素EPO引起糖尿病视网膜病

自从1989年以来,医师们便将激素红细胞生成素(EPO)处方用于治疗由失血、肾衰竭以及癌症疗法所引起的贫血.EPO对制造红细胞是很合适的,但是现在日本研究者报道,EPO会损害人的视力.科学家发现,在工业化地区的晚期糖尿病视网膜病人的眼中,超乎寻常的高浓度EPO是非年老的成年中失明的主要原因.在2005年8月NewEnglandJournal of Medicine(NEJM)上,研究者提示,抑制EPO可减轻这类视网膜病.然而,研究者承认这种工作是很难的.在视网膜病病人中,某些眼病或糖尿病的高浓度血糖会引起感光视网膜的小血管出血,充盈眼球的浓厚的玻璃体液也可能发…     

促红细胞生成素(EPO)

一、产品概述 促红细胞生成素(Erythropoietin,EPO)主要是在肾脏中产生的一种造血激素,是具有166个氨基酸残基,分子量为35000的糖蛋白。 EPO对原红细胞集落生成细胞CFU-E或其早幼阶段的BFU-E起作用,具有促进向红细胞前体细胞--网状红细胞,原红细胞的分化,并生成红细胞的作用。     

Right to die with dignity?

The right to die with dignity is an ill-defined concept, with multiple, often inappropriate, interpretations. The current proposition is that the physician take full responsibility for protecting the patients rights, for ensuring a rational use of resources and for overseeing the decision-making process such that the information is adequate and the steps proportioned. This responsibility extends not only to the health status of the patient situation, to the patients prognosis, and to his/her expectations and wishes, but also to the benefits foreseen and to the cost-benefit ratio. Emphasis is placed on two aspects of this relationship. First, dignity can be interpreted in many ways and sometimes, in the name of dignity, the patient is exposed (or exposes him/herself) to suffering, pain and complications that can be avoided. Second, when no reasonable probability of survival is present and a better quality of life is impossible, efforts are better redirected to offering a better quality of death.     

What's wrong with correlative experiments?

Here, we make a case for multivariate measurements in cell biology with minimal perturbation. We discuss how correlative data can identify cause-effect relationships in cellular pathways with potentially greater accuracy than conventional perturbation studies.